Medical science liaison
A medical science liaison (MSL) is a healthcare consulting professional who is employed by pharmaceutical, biotechnology, medical device, and managed care companies. Other job titles for medical science liaisons may include medical liaisons, medical science managers, regional medical scientists, and regional medical directors.
The term "MSL" was originally trademarked by Upjohn as "Education services – namely, initiation of drug studies in laboratory and clinical settings and development of workshops, symposia, and seminars for physicians, medical societies, specialty organizations, academicians, in concert, concerned with drug related medical topics" in 1967 and with first use in commerce in 1967.
As the number of MSL programs in healthcare increased, subsequent peer-reviewed journal publications and books became available to examine the emerging role of medical affairs  and the use of MSLs in an increasingly vertically integrated biotechnology industry.
MSLs build relationships with key opinion leaders or thought leaders and health care providers, providing critical windows of insight into the market and competition. Through such monitoring, MSLs can gain access to key influencers by interacting with national and regional societies and organizations. Moreover, as MSLs specialize in a particular therapeutic area and have scientific knowledge related to it they are now highly involved in activities related to clinical trials.
- United States Patent and Trademark Office Serial Number 73176757
- Malecha, S. E., Wiejowski, S. A. & Holt, R. J. (2000). "The applied therapeutics team: an innovative model of drug information in the pharmaceutical industry". Drug Inform. J. 34 (4): 1069–1075. doi:10.1177/009286150003400411.
- Wolin, M. J., Ayers, P. M. and Chan, E. K. (2001). "The emerging role of medical affairs within the modern pharmaceutical company". Drug Inform. J. 35 (2): 547–555. doi:10.1177/009286150103500225.
- Chin, J. (2004). "Biotechnology's special forces: ﬁeld-based medical science liaisons". J. Comm. Biotechnol. 10 (4): 1–7. doi:10.1057/palgrave.jcb.3040088.